“Moderna Way: Pioneering mRNA” – by Rami Suzuki, Ph.D., President and Representative Director, Moderna Japan.
Webinar event by HBS Club of Japan (HBSCOJ) and American Chamber of Commerce in Japan (ACCJ).
Date/time: Thursday, November 10th, 2022, 18:00-19:00 PM JST via Zoom
Language: English
Please register from here: https://us06web.zoom.us/webinar/register/WN_hDjSobGnRDqD9zOsQHpJLA
Moderna Way: Pioneering mRNA
Moderna is one of the most successful companies reached 46 Billion $ Market Capitalization, with the mission “To deliver on the promise of mRNA science to create a new generation of transformative medicines for patients”. Moderna is also selected as one of the most innovative company globally, ranking 7th, by Boston Consulting Group in 2022. An mRNA can teach the body how to make a specific protein that can help your immune system prevent or treat certain diseases. This is an entirely different approach from the conventional medicines we see today. Moderna Japan is committed to bringing innovative solutions to patients in Japan by closely collaborating with researchers, healthcare professionals, and authorities.
Japan is one of Moderna’s key markets with strategic investments with a recent visit Global CEO Stéphane Bancel and leadership team. President and Representative Director Rami Suzuki took the role to enhance Moderna success and make Japan transformation happen one year ago in November 2021. In this event organized jointly by HBSCOJ and ACCJ, she will reflect her experiences how Moderna Japan achieved tremendous growth in Japan, and what is coming next.
Moderna's mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. There will be valuable learnings from a global corporation implementing a successful scientific and business transformation in Japan.
Rami Suzuki, Ph.D.
President and Representative Director, Moderna Japan.
Prior to joining Moderna, she was the CEO and Representative Director of Ferring Japan. She was also at Janssen Japan as the head of Medical Affairs Function and at Eisai Co., Ltd. as a corporate officer in charge of corporate business development.
She obtained her Ph.D. in Medicine at University College London with a scholarship from Ludwig Institute for Cancer Research. Her postdoctoral research was on breast cancer at Imperial College, London.